HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: Comparison of statistical methods for measurement

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 1, 1999, Pages 19-30

  Lubaki, N M ^a   Shepherd, M E ^a   Brookmeyer, R S ^a   Hon, H ^a   Quinn, T C ^a   Kashamuka, M ^a   Johnson, M ^a   Gottle, R ^a   Devers, J ^b   Lederman, H M ^b   Bollinger, Robert C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CD4 count; CD8+CD38 DR ; Cytolytic T lymphocytes; HIV; Viral load

Indexed keywords

ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LEUKOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

EID: 0345411647     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199909010-00003     Document Type: Article

References (27)

1. Walker BD, Chakarabarti S, Moss B, et al. HIV-specific cytotoxic T-lymphocytes in seropositive individuals. Nature 1987;382: 345-8.
2. Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, hostrange-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis 1995;171:1623-7.
3. + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-42.
4. Lubaki MN, Egan MA, Siliciano RF, Weinhold KJ, Bollinger RC. A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses 1994;10:1427-31.
5. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995:122:573-9.
6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
7. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-10.
8. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology, vol 2. New York: John Wiley & Sons, 1996:7.18.6.
9. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
10. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
11. Margolick JB, Volkman DJ, Lane HC, Fauci AS. Clonal analysis of T lymphocytes in the acquired immunodeficiency syndrome. Evidence for an abnormality affecting individual helper and suppressor T cells. J Clin Invest 1985;76:709-15.
12. + T cells and HIV-1 - Response. Science 1998;279:1436.
13. + T cell responses associated with control of viremia [see comments]. Science 1997;278:1447-50.
14. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-56.
15. Grant MD, Smaill FM, Singal DP, Rosenthal KL. The influence of lymphocyte counts and disease progression on circulating and inducible anti-HIV-1 cytotoxic T-cell activity in HIV-1-infected subjects. AIDS 1992;6:1085-94.
16. Huang XL, Fan Z, Liebmann J, Rinaldo C. Detection of human immunodeficiency virus type-1-specific memory cytotoxic T lymphocytes in freshly donated and frozen-thawed peripheral blood mononuclear cells. Clin Diagn Lab Immunol 1995;2:678-84.
17. + cell levels. J Infect Dis 1994;170:775-81.
18. Lubaki NM, Ray SC, Dhruva B, Quinn TC, Siliciano RF, Bollinger RC. Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in individuals without clinical progression. J Infect Dis 1997;175:1360-7.
19. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-74.
20. Dalod M, Harzic M, Pellegrin I, et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998;178:61-9.
21. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:585-92.
22. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis 1997; 176:118-25.
23. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
24. Rinaldo CR Jr, Beltz LA, Huang XL, Gupta P, Fan Z, Torpey DJ III. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 1995;11:481-9.
25. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18: 332-40.
26. + lymphocyte activity. J Infect Dis 1995;172:329-39.
27. + T cells predicts HIV disease progression. Cytometry 1998;33:133-7.